This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
新药开发进度
上疗漾专区
Chemo young (MS-20)
Microbio spent 14 years and invested more than NT$1 billion in the research and development of “Chemo young” oral solution. It is a new oral cancer drug developed in accordance with international new drug development standards, and it was approved for use as an adjuvant therapy new drug for cancer in Taiwan. It can effectively improve the fatigue and loss of appetite caused by chemotherapy and improve the ability of cancer patients to maintain family and social activities. Its clinical efficacy is evident. Due to its good safety, Taiwan FDA approved it as an OTC drug for sale. It can be sold in hospitals, clinics, pharmacies and other places where Chinese or Western doctors or pharmacists are stationed. It is not constricted to doctor’s prescription, which is a great boon for cancer patients. The company-initiated clinical trial of MS-20 in combination with Pembrolizumab (anti-PD1 therapy) for the treatment of metastatic non-small cell lung cancer (NSCLC) is currently ongoing. Obtaining the GRAS conclusion will facilitate the product launch to global markets following the completion of the trial.
Chemo young (MS-20)
Microbio spent 14 years and invested more than NT$1 billion in the research and development of “Chemo young” oral solution. It is a new oral cancer drug developed in accordance with international new drug development standards, and it was approved for use as an adjuvant therapy new drug for cancer in Taiwan. It can effectively improve the fatigue and loss of appetite caused by chemotherapy and improve the ability of cancer patients to maintain family and social activities. Its clinical efficacy is evident. Due to its good safety, Taiwan FDA approved it as an OTC drug for sale. It can be sold in hospitals, clinics, pharmacies and other places where Chinese or Western doctors or pharmacists are stationed. It is not constricted to doctor’s prescription, which is a great boon for cancer patients. The company-initiated clinical trial of MS-20 in combination with Pembrolizumab (anti-PD1 therapy) for the treatment of metastatic non-small cell lung cancer (NSCLC) is currently ongoing. Obtaining the GRAS conclusion will facilitate the product launch to global markets following the completion of the trial.